The Skinny On Labeling For Orexigen’s Contrave
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech finally gains approval for its obesity agent and receives a label from FDA that, despite multiple contraindications and a boxed warning, is being looked upon favorably.